Opus Genetics (IRD) Current Leases (2019 - 2020)
Opus Genetics (IRD) reported Current Leases of $100397.0 for Q3 2020, down 25.66% year-over-year from $135052.0 in Q4 2019, and down 26.29% on a QoQ basis from $136197.0 in Q2 2020.
Opus Genetics (IRD) has 2 years of Current Leases data on file, last reported at $100397.0 in Q3 2020.
- Quarterly Current Leases fell 25.66% year-over-year to $100397.0 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $100397.0 (down 25.66% YoY) and the FY2019 annual result came in at $139765.0, changed N/A from the prior year.
- Current Leases retreated to $100397.0 in Q3 2020 per IRD's latest filing, from $136197.0 in the prior quarter.
- Across five years, Current Leases topped out at $144610.0 in Q1 2020 and bottomed at $100397.0 in Q3 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,991.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 720.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 45.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 100,397.00 |
| Jun 30, 2020 | 136,197.00 |
| Mar 31, 2020 | 144,610.00 |
| Dec 31, 2019 | 139,765.00 |
| Sep 30, 2019 | 135,052.00 |
| Jun 30, 2019 | 130,466.00 |
| Mar 31, 2019 | 113,531.00 |